


## Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities

Chiara F. Magnani, ... , Alessandro Rambaldi, Andrea Biondi

*J Clin Invest.* 2020. <https://doi.org/10.1172/JCI138473>.

Clinical Medicine In-Press Preview Clinical trials Hematology

### Graphical abstract



Find the latest version:

<https://jci.me/138473/pdf>



**Title: Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities**

Chiara F Magnani<sup>1</sup>, Giuseppe Gaipa<sup>1,2</sup>, Federico Lussana<sup>3</sup>, Daniela Belotti<sup>2,4</sup>, Giuseppe Gritti<sup>3</sup>, Sara Napolitano<sup>5</sup>, Giada Matera<sup>1,2</sup>, Benedetta Cabiati<sup>1,2</sup>, Chiara Buracchi<sup>1</sup>, Gianmaria Borleri<sup>3</sup>, Grazia Fazio<sup>1</sup>, Silvia Zaninelli<sup>6</sup>, Sarah Tettamanti<sup>1</sup>, Stefania Cesana<sup>1,2</sup>, Valentina Colombo<sup>1,2</sup>, Michele Quaroni<sup>1,2</sup>, Giovanni Cazzaniga<sup>1</sup>, Attilio Rovelli<sup>5</sup>, Ettore Biagi<sup>1,5</sup>, Stefania Galimberti<sup>7</sup>, Andrea Calabria<sup>8</sup>, Fabrizio Benedicenti<sup>8</sup>, Eugenio Montini<sup>8</sup>, Silvia Ferrari<sup>3</sup>, Martino Introna<sup>3,6</sup>, Adriana Balduzzi<sup>4,5</sup>, Maria Grazia Valsecchi<sup>7</sup>, Giuseppe Dastoli<sup>1</sup>, Alessandro Rambaldi<sup>3,9</sup>, Andrea Biondi<sup>1,2,5</sup>.

<sup>1</sup>Tettamanti Research Center, Department of Pediatrics, University of Milano - Bicocca/Fondazione MBBM, Monza, Italy; <sup>2</sup>Laboratorio di Terapia Cellulare e Genica Stefano Verri, ASST-Monza, Ospedale San Gerardo, Monza, Italy; <sup>3</sup>Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy; <sup>4</sup>Department of Pediatrics, University of Milano - Bicocca, Milan, Italy; <sup>5</sup>Clinica Pediatrica University of Milano - Bicocca/Fondazione MBBM, Monza, Italy; <sup>6</sup>USS Centro di Terapia Cellulare "G. Lanzani", Bergamo, Italy; <sup>7</sup>Bicocca Bioinformatics, Biostatistics and Bioimaging Centre, Department of Medicine and Surgery, University of Milano - Bicocca, Milan, Italy; <sup>8</sup>San Raffaele Telethon Institute for Gene Therapy (SR-TIGET) / IRCCS San Raffaele Scientific Institute, Milan, Italy; <sup>9</sup> Department of Oncology and Hematology, University of Milan, Italy

**Address correspondence to:**

Andrea Biondi, Department of Pediatrics, University of Milano - Bicocca, Fondazione MBBM / Ospedale San Gerardo, Via Pergolesi, 33, 20900 Monza, Italy.

Phone: +39-039-2333513, [e-mail: abiondi.unimib@gmail.com](mailto:abiondi.unimib@gmail.com)

**Authorship note:** CFM and GG share first authorship, AR and AB are co-senior authors.

Ettore Biagi's present address is: Clinical R&D, Celgene, Boudry, Neuchatel, Switzerland.

Chiara F Magnani's present address is: Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

**Conflict of Interest:** Tettamanti Foundation has filed a patent application of the technology used in this report (European patent Application No. 15801344.1; PCT/EPO2015/075980), and C.F.M., S.T., E.B. and A.B. are inventors. The technology was licensed to Formula Pharmaceuticals, Inc. (Berwyn, PA), for further development. Formula Pharmaceuticals provided a research grant to support the current academic study.

**One sentence summary:** Donor-derived CD19 CAR cytokine induced killer (CIK) cells engineered with the Sleeping Beauty transposon demonstrates high expansion, low toxicity and lead to complete remission in r/r B-ALL

## **Abstract**

**Background.** Chimeric antigen receptor (CAR) T cell immunotherapy has achieved complete remission and durable response in highly refractory patients. However, logistical complexity and high costs of manufacturing autologous viral products limit CAR T cell availability.

**Methods.** We reported the early results of a phase I/II trial in B-cell acute lymphoblastic leukemia (B-ALL) patients relapsed after allogeneic hematopoietic stem cell transplantation (HSCT) using donor-derived CD19 CAR T cells generated with the Sleeping Beauty (SB) transposon and differentiated into cytokine induced killer cells (CIK).

**Results.** The cellular product was produced successfully for all patients from the donor peripheral blood (PB) and consisted mostly of CD3+ lymphocytes with 43% CAR expression. Four pediatric and 9 adult patients were infused with a single dose of CAR T cells. Toxicities reported were two grade I and a grade II cytokine release syndrome (CRS) cases at the highest dose, in the absence of graft-versus-host disease (GvHD), neurotoxicity, or dose-limiting toxicities. Six out of 7 patients, receiving the highest doses, achieved CR and CRi at day 28. Five out of 6 patients in CR were also minimal residual disease (MRD)-negative. Robust expansion was achieved in the majority of the patients. CAR T cells were measurable by transgene copy PCR up to 10 months. Integration site analysis showed a positive safety profile and highly polyclonal repertoire in vitro and at early time points after infusion.

**Conclusion.** SB-engineered CAR T cells expand and persist in pediatric and adult B-ALL patients relapsed after HSCT. Anti-leukemic activity was achieved without severe toxicities.

**Trial registration.** [clinicaltrials.gov NCT03389035](https://clinicaltrials.gov/ct2/show/study/NCT03389035).

**Funding.** This study was supported by grants from AIRC; CRUK; FC AECC; Ministero della salute

## Introduction

Significant efforts over the past few years led Chimeric Antigen Receptor (CAR) T cell therapy to success in relapsed and refractory (r/r) B-cell malignancies. The early concept evaluated in experimental academic clinical trials moved to real-world practice, confirming the impressive clinical results (1). In r/r B-cell acute lymphoblastic leukemia (B-ALL), whose chance of survival is estimated 10-30% at 5 years with conventional therapy (2–4), minimal residual disease (MRD)-negative complete remission (CR) rates were observed at 1 month after CAR T cell infusion in 63-93% of the patients with an overall survival (OS) of 60-80% at 6 months in multiple studies (5–10). Still a significant heterogeneity in clinical outcomes was observed when comparing pediatric and adult patients, different CAR T cell products and transduction modalities (11). In addition, logistical complexity, high costs and toxicities are currently the main barriers to the use of CAR T cell therapy. Production and handling of viral vectors are time-consuming, need specialized biosafety level 2 (BSL2) facilities, and trained staff resources. Furthermore, patient-derived CAR T cell production may be limited due to failure to collect sufficient T cells or to expand products in selected patient populations who received intensive chemotherapy. Notably, patients with a T-cell signature predicting for dysfunctional response or with high leukemic blast contamination might benefit from donor-derived products (12–14).

We therefore propose non-viral engineering of an allogeneic T cell population according to cytokine induced killer (CIK) cell protocol of differentiation (15). This population is characterized by the enrichment of CD3+CD56+ cytotoxic cells and a high profile of safety leading to minimal occurrence of graft versus host disease (GvHD) after allogeneic CIK (16–18). Sleeping Beauty (SB) is an integrating vector belonging to the Tc1/mariner family of DNA transposon that was reconstructed by inverse engineering of an inactive gene in fish genome (19, 20). The SB transposon vector allows for permanent genetic modification through stable integration of the transgene cassette, conferring

prolonged expression in T cells. The SB vector has recently been validated in clinical trials for the manufacture of CAR T cells (21) which were selectively propagated ex vivo with multiple stimulations in the presence of artificial antigen presenting cells (AaPCs). We have previously reported an improved platform of non-viral engineering using the SB vector which consist of a single stimulation step and was applied for different CAR molecules including anti- CD19, CD123 and BAFFR (22, 23). Herein, we report the clinical application of this concept to treat adult and pediatric patients with B cell-ALL (B-ALL) relapsed post allogeneic hematopoietic stem cell transplantation (allo-HSCT) by using non-viral CD19-specific CARCIK cells (CARCIK-CD19) manufactured from the previous transplant donor. These data demonstrate the feasibility and safety of our manufacturing platform and support further clinical application of non-viral allogeneic CAR T cell products.

## Results

### *Product manufacturing*

Non-viral SB-engineered CAR T cells were produced according to our previously established platform (24) and named CARCIK-CD19 (CAR cytokine induced killer cells specific for CD19). We chose to differentiate T cells to generate a memory T-cell population according to CIK cell protocol as the incidence of GvHD is usually less prevalent using memory cells (17, 25). An objective of our study was to determine the feasibility and reproducibility of manufacturing and releasing donor-derived non-viral products with a level of CAR expression higher than 20%, an enrichment in CD3+CD56+ T cells higher than 30%, a cell viability higher than 80%, in vitro potency higher than 25%, and safety compliance. Cellular products were generated starting from 50 ml of peripheral blood (PB) from the previous transplant donor, by electroporation of total PB mononuclear cells (PBMC) with SB plasmids expressing a CD19 third generation CAR incorporating the CD28 and OX40 costimulatory domains (Supplemental Figure 1A). The CARCIK-CD19 batches prepared for clinical use were derived from 3 HLA identical siblings (ISD), 4 matched unrelated donors (MUD), and 6 haploidentical donors (Haplo). After electroporation, cells were expanded by using a single stimulation with anti-CD3 and IFN- $\gamma$  and IL-2 for T cell expansion (Supplemental Figure 1B). In total we manufactured 19 batches by seeding a median of  $129.3 \times 10^6$  allogeneic PBMCs. Three of these 19 batches were manufactured for the purpose of good manufacturing practices (GMP) process validation starting from PB of voluntary donors, whereas 16 batches were produced for clinical use from 12/20/2017 to 07/30/2019. At the end of the expansion process, a mean of  $6.91 \times 10^9$  nucleated cells (range  $1.39 - 20.0 \times 10^9$ , Figure 1A) was harvested with a mean fold increase of 71.08 (range 14.41 – 338.8, Supplemental Figure 2A). Manufactured cells had high level of viability (mean  $96.06\% \pm \text{SD } 2.60\%$ , range 89.10% - 98.90%) and were mostly CD3+ lymphocytes (mean  $98.92\% \pm \text{SD } 1.24\%$ ) with high killing activity and effector memory phenotype (Figure 1B-D and Supplemental Figure 2B-C). Of

these, a mean of 43.05% (range 15.10%-73.17%) were CAR+, 46.85% (range 31.62%-71.80%) were CD56+, and 80.90% (range 55.80%-93.20%) were CD8+, with a median number of transgene copies per cell of 3.54 (range 0.62-4.92, Figure 1D and Supplemental Figure 2D). The majority of CD3+CAR+ T cells had a CD8+ effector memory phenotype (Figure 1E-F). The median length of cell-product manufacturing was 23 days (range, 20-32 days) and batches could be released 7-10 days after the production ended. All the enrolled patients had successful manufacturing of a CARCIK-CD19 batch (Supplemental Table 1). The quality requirements for batch release were met in 15 out of 19 productions. One batch was rejected due to a bacterial contamination. Another batch, manufactured for the same patient, was released and infused according to the original treatment schedule. Three batches partially deviated from specifications, due to a lower level of CAR expression (15.01% CD3+CAR+ instead of  $\geq 20\%$ ) and a higher value of transposase expression, (41.68 and 97.06, respectively instead of  $< 20$  copies/10000 GUS), but largely below the safety limit for a possible enzyme activity (26) (Supplemental Figure 2E). However, the out of specification batches were infused (patient 6, 12 and 13), as per clinical decision based on the absence of any alternative treatment options (27).

### *Clinical trial*

We designed a multicentric clinical study (ClinicalTrials.gov NCT03389035) to assess the safety and feasibility of infusing allogeneic CARCIK-CD19 in patients with B-ALL relapsed after HSCT. The trial followed a four-dose escalation scheme ( $1 \times 10^6$ ,  $3 \times 10^6$ ,  $7.5 \times 10^6$  and  $15 \times 10^6$  transduced CARCIK-CD19 cells/kg) using the Bayesian Optimal Interval Design (BOIN). From January 2018 to November 2019, a total of 20 patients were screened, and 16 were enrolled (Figure 2). Two patients were excluded from receiving lymphodepletion chemotherapy and cell infusion, one due to rapid disease progression leading to premature death and one to acquisition of a myeloid phenotype. An



additional patient decided to withdraw from the study. A total of 13 patients, four children and 9 adults, proceeded to lymphodepletion and treatment with a single infusion of CARCIK-CD19 product, with a median time from enrollment to infusion of 76.6 days (range 50-107 days). Median age was 32 years (range 2-63 years). All patients had undergone multiple prior lines of therapy (median of 2, range 1-7), and at least one allogeneic transplant, with a median of 9 months (range 2-30 months) from allo-HSCT to relapse. Seven out of 13 patients experienced acute and/or chronic GVHD post allo-HSCT and were treated with steroids (5/13), steroid and Tracolimus (1/13) or Infliximab (1/13). The bone marrow (BM) blast count at enrollment ranged from 5% to 98% and 4 patients presented active extramedullary diseases (Table 1). Notably, the median LDH, platelet and neutrophil count pre-lymphodepletion were 306 U/L (range 148-595 U/L), 68,000 platelets/mmc (range 12,000-237,000 platelets/mmc) and 650 neutrophils/mmc (range 60-4,150 neutrophils/mmc), respectively, reflecting the aggressive progression of the disease which indeed required bridging therapy before infusion for all the patients (Table 1 and Supplemental Table 2).

#### *Engraftment and expansion of CAR T cells*

Detectable peripheral CAR T cell engraftment was observed in 13/13 patients (100%) by transgene copies quantitative evaluation and in 12/13 patients (92.9%) by flow cytometry using a recombinant human CD19 protein, with robust expansion ( $> 100,000$  copies per  $\mu\text{g}$  DNA and  $> 40$  cells per  $\mu\text{l}$ ) achieved in 8/13 patients (Figure 3A-C). The median time to maximal expansion was 14 days (range 7-22 days) and the maximal expansion reached about  $1 \times 10^6$  transgene copies per  $\mu\text{g}$  DNA and 70% of CAR<sup>+</sup> T cells in PB with a median area under the curve (AUC) from day 0 to day 28 of  $1.08 \times 10^6$  copies per  $\mu\text{g}$  DNA (range 3,915.5- $4.80 \times 10^6$ , Supplemental Table 3). Engrafted CAR T cells were detected also in BM (Supplemental Figure 3A-B). CAR T cells were effective in promoting ablation of malignant CD19<sup>+</sup> cells in PB and BM. CD19<sup>+</sup> cell ablation was achieved in association with expansion

and persistence of CAR T cells, even in a patient with massive BM blast infiltration persisting after lymphodepletion (Figure 3D). CAR T cell expansion was influenced by the dose level, in terms of exposure (median AUC-28d  $6.0 \times 10^5$ ,  $5.3 \times 10^4$ ,  $1.3 \times 10^6$  and  $2.2 \times 10^6$  for patients treated with dose level 1, 2, 3, 4, respectively) and time to reach expansion (Figure 3E-G), as well as by the tumor burden after lymphodepletion (median AUC-28d  $3.4 \times 10^5$  and  $2.7 \times 10^6$  and Cmax-28d  $4.2 \times 10^4$  and  $3.8 \times 10^5$  for patients with < or > 15% tumor burden, respectively). Interestingly, expansion was similar in pediatric and adult patients, and did not depend on the type of donor (Supplemental Figure 3C-F). CD8+ T cells represented the predominant circulating CAR+ T cell subset along with CD3+CD56+ CIK cells and CD4+ T cells to a lesser extent. Persistence of central memory CAR+ T cells was observed after infusion. The majority of CAR T cells had a central and effector memory phenotype in vivo (Figure 4A-C). Twelve out of 13 patients had detectable CAR T cells measured as transgene copy number at the last available assessment with a median duration of 94 days (range, 22 to 300 days).

### *Toxicity*

Toxicities are summarized in Table 2 and Supplemental Table 4. The infusion was uneventful in all patients except one pediatric patient (patient 6), who experienced generalized seizures, tachycardia and loss of consciousness due to a dimethyl sulfoxide (DMSO) reaction, which rapidly responded to diazepam. No further infusion related reactions were observed. Two grade I and one grade II cytokine release syndrome (CRS) cases (assessed with criteria in Lee et al. (28), Supplemental Table 4) occurred in three patients treated with the highest dose. CRS was associated with increased concentrations of serum cytokines (Supplemental Figure 4). Patient 12, who was the only patient experiencing grade II CRS, with fever and hypoxia, required low-flow oxygen (FiO<sub>2</sub> <40%) and treatment with 2 doses of tocilizumab with benefit and resolution of symptoms. The day of the

infusion, patient 5 experienced pneumonitis with acute respiratory distress, which required oxygen therapy and antibiotics; tocilizumab was also infused at day +1 after infusion, as CRS could not be excluded at the time. On day + 10, for a worsening of respiratory failure, the patient has been transferred in intensive care unit (ICU) where she received non-invasive ventilation. Clinical improvement followed methylprednisolone and further antibiotic changes. Deep pancytopenia was reported in two out of 13 patients, and severe infections in four patients. Consistent with the concomitant in vivo detection of CAR T cells, B cell aplasia (BCA) was observed in all treated patients. Six of these patients had persistent BCA at the last follow-up with a median duration of 3 months (Figure 5A). None of the treated patients developed immune-effector cell neurotoxicity syndrome (ICANS). Furthermore, the persistent engraftment of allogeneic CAR T cells was not associated to any sign or symptom of GVHD, although some patients had experienced GVHD post previous allo-transplant.

#### *Response data*

The overall response rate (CR/CRi) rate was 61.5% (8 out of 13 patients, 95%CI=31.6-86.1%). Six out of 7 patients, receiving the two highest doses, achieved CR/CRi with an overall response rate at day 28 post infusion of 85.7% (95%CI=42.1-99.6%, Figure 5B and Table 2). Patient 6 experienced BM remission but persistent extramedullary disease with a mixed CD19+/CD19- phenotype and was not accounted as a responder, accordingly. MRD was assessed by both multiparametric flow cytometry and PCR for leukemia-specific immunoglobulin- (IG)/T-cell receptor (TR) gene rearrangements in all responder patients. Five out of the 6 patients (83.3%, 95%CI=35.9-99.6%) in CR at the highest doses were also MRD-negative. MRD-negative status for all responders was achieved by 75% (6 out of 8, 95%CI=34.9-96.8%). The two patients in CR but with MRD+ relapsed with a CD19+ disease at +2.3 and +1.9 months post infusion, respectively, and one of them is alive and receiving salvage therapy.

Among the 6 patients who achieved MRD-negative CR, two children underwent consolidation with a second allo-HSCT and are still alive and disease free (+14 and +10 months), two adult patients died of subsequent CD19+ disease relapse and two adult patients, who did not undergo allo-HSCT, are still alive and disease free (+12 and +9 months) without additional therapies, at +9 months from the data cut-off date. Interestingly, patient 12 relapsed post allo-HSCT with a diffuse B-ALL presenting elevated S-Aspartate aminotransferase/S-Alanine aminotransferase (AST/ALT: 157/287UI/L), S-gamma Glutamyl Transpetidase (gammaGT: 1,183 UI/L) and Bilirubin (Bil: 18.8 mg/dl) due to malignant liver infiltration. CT-scan performed 44 days post treatment showed shrinking of the tumor mass associated with recovery of liver function (AST/ALT: 12/58 UI/L, Gamma GT: 82 UI/L, Bil 0.8 mg/dl) (Figure 5C). This latter case indicated the ability of CIK cells to infiltrate large tumor masses (29) and to tackle extramedullary leukemia. Such ability was further corroborated by the detection of massive infiltration of CAR T cells in the 2L pleural effusion. The overall median follow-up among the patients who received CARCIK-CD19 infusion was 8.7 months (range 1.02-20.03 months). So far four of the 7 patients treated with the last two highest dose levels are alive and in complete remission with a median follow-up of 6.9 months as of the data cut-off date, whereas 3 adult patients relapsed, all with retention of CD19 antigen expression.

#### *Integration site analysis*

We performed a comprehensive integration site (IS) analysis on genomic DNA extracted from the medicinal product batches at release and from the PB of 13 treated patients, harvested at different time points (ranging from 7 to 28 days) after infusion. Moreover, we also analyzed a BM sample from a single patient (strategy depicted in Figure 6A). For the retrieval of SB IS we adopted a technique similar to the Linker Mediated (LM)-PCR (30), where the genomic DNA is sheared by sonication, ligated to a DNA linker cassette, and amplified by PCR using oligonucleotides

complementary to the vector sequence and the linker cassette bound to the shear site and then sequenced (public data accession number PRJNA643365). On average, CARCIK-CD19 batches yielded a higher amount of PCR products compared to in vivo samples (Supplemental Figure 5). By this approach we identified a total of 101,020 and 88,034 IS in in vitro and in vivo samples, respectively (Supplemental Table 5). The relative number of retrieved IS for each sample was proportional to the marking levels (Supplemental Figure 6). The distribution of SB IS around the Transcription Start Site (TSS) showed no bias to integrate near promoter sequences (Figure 6B). Gene ontology enrichment analysis, performed with Genomic Regions Enrichment of Annotations Tool (GREAT), revealed a significant enrichment of genes involved in T-cell biology including T-cell activation, differentiation and proliferation (Supplemental Figure 7). To identify additional signs of insertional mutagenesis we searched for Common Insertion Sites (CIS). We identified sporadic CIS in single patients and targeting nearby genes by a relatively small number of IS (3 to 5) and none of them was classified as cancer related gene (Figure 6C and Supplemental Figure 8). All in vitro and in vivo samples harvested at early time points, showed a highly polyclonal repertoire, reaching thousands of distinct IS in several samples, with the most represented IS in terms of abundance of 4%. All patients showed identical IS persisting over different time points although no clonal expansions were observed in any patient. However, at later time points ( $\geq 28$  days after infusion) the repertoire of IS showed a marked reduction towards oligoclonality, which was further evidenced by the analysis of the Shannon diversity index (Figure 6D-E and Supplemental Figure 9). The increase in clonal abundance in the late datasets was similar among all IS and were not enriched for IS targeting cancer related genes, suggesting that the observed oligoclonality was not caused by the appearance of specific dominant clones but rather the result of the reduction in the number of retrieved IS.

## Discussion

This study provides the first evidence that donor-derived cells, engineered with the Sleeping Beauty transposon, is a safe and valid therapeutic option for B-ALL patients relapsed after allo-HSCT. This platform reproducibly produces CARCIK-CD19 cellular products starting from small amount of donor derived peripheral blood. Manufactured cells were able to expand rapidly and efficiently in vivo, with persistence measurable for up to 10 months in patient's blood and bone marrow. The infusion of CARCIK-CD19 was remarkably safe in all treated patients since CRS incidence and grade were negligible, and acute GVHD and neurotoxicity never observed. At the higher dose levels, a significant rate of hematological and molecular response was achieved. Most of the responders are still in remission with an average follow-up of 6 months. Therefore, early results from our trial suggest that allogeneic non-viral manufacturing is a valid strategy to generate CAR-mediated immunotherapy.

So far, manufacture of CAR T cells, including the existing FDA and EMA-approved products, has relied on viral vectors, which takes a minimum of two weeks for production and requires multiple steps and quality assessments (5, 31–33), leading to costs as high as about 30% of the cost of the entire process and difficulties in securing a time effective viral supply. In our study we showed that 50 ml of blood were largely enough for manufacturing sufficient numbers of CARCIK-CD19 for 13/13 patients. The process has a relatively low cost of goods, with an estimated cost ranging from 5 to 10 times lower than viral processes, with an average transduction efficiency and final cell viability comparable to viral vectors. Potential weakness of our study is represented by the duration of in vitro culture currently required to generate CARCIK-CD19 cells, mainly due to the mandatory complete clearance of the SB11 transposase activity. SB11 transposase-expressing plasmid, though bearing the transiently active cytomegalovirus early promoter, causes at low frequency extended transposase protein expression which could potentially lead to remobilization of the transposon in other genomic compartments (34). For a further platform implementation, the hyperactive SB100X

(35) variant in mRNA (36) or protein (37) version could be used. These alternatives may lead to a level of integration of SB minicircles up to 45% and 20-30%, respectively, thus avoiding the theoretical risk of chromosomal integration, and reducing the time of in vitro culturing.

The rationale of using donor-derived memory T cells as CIK cells over conventional CAR T cells comes from clinical experiences clearly demonstrating safety and tolerability of repeated CIK cell infusions with minimal and manageable GVHD occurrence (17, 18, 38). Minimal GVHD results from acquisition of a NK-like MHC-unrestricted cytotoxicity during stimulation with CD3, IFN- $\gamma$  and differentiation in the presence of IL-2 (29). In our study we observed no occurrence of GVHD even in the context of patients who have undergone haplo-HSCT and accordingly received CARCIK-CD19 cells from their haplo-identical donor. Interestingly, even patients who experienced GVHD after the initial HSCT did not show any signs of GVHD post CARCIK-CD19 produced from the PB of the same allogeneic donor. The absence of GVHD occurrence was consistent with recent clinical studies with donor-derived memory T cells post allo-HSCT (25). The small amount of starting material and the lack of GVHD activity paved the way for the development of an off-the-shelf product (39). In keeping with our strategy, other studies are currently exploiting the use of unrelated donor-derived TCR edited T cells (40–43) or cord blood-derived NK cells (44, 45). However with respect to NK, T cells have increased in vivo persistence, which we also reported by using CARCIK-CD19, a feature that is difficult to be achieved with nonengineered NK cells (45). Genome editing is rather limited by enrichment requirements and risk of translocations and rearrangements. Similarly to our platform, differentiation of HSC using a CD28-based CAR construct drove progeny differentiation to an NK-like phenotype (46), associated to antigen-directed antileukemic activity across MHC barriers (47). SB-engineered T cells, used as adjuvant therapy post transplantation and administered without additional lymphodepletion, showed limited expansion and persistence with an average of 201 and 51 days for autologous and allogeneic recipients, respectively, in the absence of B-cell aplasia (21).

In our study we found excellent expansion of infused CAR T cells with a cumulative exposure of  $1.08 \times 10^6$  copies per  $\mu\text{g}$  DNA, as assed by the median AUC, and a median time to maximal expansion of 14 days which was comparable to those reported in previous studies in pediatric and adult patients treated with second-generation viral CD19CARs (10, 48). Likewise, expansion was associated with clinical activity and led to BCA. Interestingly, patients with higher tumor burden persisting after lymphodepletion experienced higher exposure and reached maximal expansion faster, which further corroborates the observation that antigen-driven stimulation drives CAR T cell expansion (12). While it has been clearly demonstrated that tumor burden is an important factor contributing to CAR T cell expansion, the impact of cell dose infused remains controversial (7, 49). An association between cell dose and CAR T cell expansion was observed, which may be determined by the prevalence of effector memory phenotype in the cell product. The most effective treatment doses were higher than the T cell dose previously reported for other CAR T cell products. It is likely that the predominance of CD8+ effector memory cells, the costimulatory design and the use of SB transposon, require the infusion of higher doses of CARCIK-CD19. For the same reasons, these cells are associated with a better safety profile characterized by the absence of massive cytokine secretion. Persistent engraftment was detected at low levels up to 300 days and in the vast majority of patients at the last available measure. The use of standard lymphodepletion and the incorporation of the OX40 module in the CD28 based CAR (50) might have contributed to long-term CAR T cell persistence, as observed with combination of costimulatory domains in some third-generation CAR structures (51, 52). In association with CAR T cell massive expansion, marked cytokine increase in the serum levels and severe toxicities have occurred in most CAR T clinical trials (6–9, 49). The modulation of the typical cytokine production storm, associated with aggravation of CRS mediated by IFN- $\gamma$ , IL-6, TNF- $\alpha$  and IL-8, might explain the lower incidence of CRS and the absence of neurotoxicity despite equivalent expansion to other CAR trials (53).



We found, for the first time, that the integration profile of SB, without preferences for gene dense regions and with no bias to target regions near TSS, is maintained after infusion, suggesting a lack of selective pressure for genomic regions with different properties in vivo. Moreover, gene ontology analysis showed a significant enrichment of genes expressed in T cells, in agreement with the typical SB profile characterized by a bias to target accessible chromatin regions which, in this case, are T cell-specific, possibly due to the temporal proximity of the integration with the CD3-specific activation (22, 54). As shown previously, viral insertions in Human Immunodeficiency Virus (HIV) infected subjects may alter T cell regulatory pathways and thus promote clonal expansion and, consequently, persistence of the latent HIV reservoir (55). Similarly, vector insertions in CAR T cells might trigger clonal expansions of genetically modified cells, showing dramatic in vivo expansion of a single clone. As documented in CAR T cell trials using viral vectors, vector insertion within the *CBL* oncogene and disruption of the normal *TET2* allele were reported (56, 57). Despite a recent study has suggested that vector insertions might promote CAR T clonal expansion which correlates with positive outcome (58), we did not find any evidence that SB insertions in our trial have triggered any clonal dominance, no selection of genes targeted by CIS which have been associated with potential leukemogenic insertional events in preclinical and clinical gene therapy. Importantly, a sizeable amount of IS present in CARCIK-CD19 were also found in vivo, indicating that the progeny of infused CAR T cells was able to engraft, expand and persist overtime. At later time points, the clonal repertoire was significantly reduced, in agreement with the observed contraction phase as measured by transgene PCR and flow cytometry.

We observed a dose-dependent clinical response associated with low toxicity in a category of patients with r/r ALL following allo-HSCT (59), whose chances of survival are very low. The infusion of high CARCIK-CD19 doses induced CR/CRi in six out of seven patients, four of whom remained in remission with a median follow-up of 6.9 months as of the data cut-off date. BCA was sustained at

the last follow-up in six out of 13 patients with a median duration of 3 months. The occurrence of CD19- relapses was limited, in keeping with that reported in other adult patient series (7, 8). The limited number of pediatric patients treated so far prevent us from drawing premature statements in this setting. Overall, we are tempted to speculate that CARCIK-CD19 may exert an anti-leukemic effect which is not limited to the CAR engagement but may involve long-lasting allogeneic recognition. Furthermore, the predominance of the effector memory T cell phenotype, the large number of produced cells and their safety profile allow to design subsequent studies with multiple maintenance infusions. Despite the data look very encouraging in terms of safety and efficacy, the small number of treated patients makes it difficult to claim that this approach is as effective as commercially available CAR T cell products. Likewise, assessment of the CARCIK-CD19 production variability in relation to the treatment outcome is not possible at this time. Interestingly, the lack of GVHD activity when using HLA-mismatched donors and our ability to generate cord blood-derived CIK (39) open the possibility to use cord blood-derived CARCIK-CD19 even in patients who did not undergo HSCT. Following a deep lymphodepletion aimed to prevent rejection and allowing robust in vivo expansion, this approach may mostly benefit patients who fail collection or manufacturing of autologous CAR T cells.

## Methods

### *Manufacturing.*

CIK cells were generated from 50 ml of donor-derived PB by electroporation with the GMP-grade CD19.CAR/pTMNDU3 and pCMV-SB11 plasmids (24) (manufactured by VGXI, Inc. 2700 Research Forest Drive, Suite 180 The Woodlands, TX 77381 USA) according to the method enclosed in the filed patent EP20140192371. Full details of the manufacture and release are provided in the Methods section in the Supplemental data. Briefly, PBMCs were electroporated using 4D-Nucleofection™ (Lonza, Basel, CH) system with P3 Primary Cell 4D-Nucleofector kit (Lonza) in the presence of pT Sleeping Beauty vector expressing the FMC63-derived CD19-specific scFv fused to a CD28 transmembrane domain and the CD28.OX40.CD3 $\zeta$  signaling endodomain under the control of the synthetic MNDU3 (60) promoter and flanked by pT IR/DR sequences (20) and pCMV vector encoding the transposase SB11 gene (61). Autologous PBMCs irradiated with 60Gy of <sup>137</sup>Cs  $\gamma$ -rays were added after electroporation. IFN- $\gamma$  (1000 U/ml; Boehringer Ingelheim, Germany) was added at day 0 and IL-2 (300 U/ml; Novartis, Basel, CH) and OKT-3 (50 ng/ml; Takara, Kyoto, Japan) were added at day 1. Cells were then cultured in GMP Advanced RPMI-1640 medium (Gibco, Thermo Fisher, Waltham, Massachusetts, USA) supplemented with heat-inactivated GMP Fetal Bovine Serum (FBS, Hyclone, GE Healthcare, Chicago, Illinois, USA) for 18-28 days and IL-2 was added weekly. CARCIK-CD19 were formulated with cryopreservation (23,9% of normal saline solution for intravenous injection, 56,1% of HSA solution, at 20%, 10% of DMSO and 10% of ACD-A).

### *Study design.*

The study is conducted at the Pediatric Clinic of Milano - Bicocca University/MBBM Foundation in Monza, Italy, for 1-17 years old patients, and at the Papa Giovanni XXIII Hospital of Bergamo, Italy, for patients older than 18 years. The target population consists of patients with B-ALL who are either

refractory or relapsed after allo-HSCT. Here we report the early results on the first 13 patients infused, with data frozen as of 30 November 2019. Details regarding enrollment are provided in the Methods section in the Supplemental data. After lymphodepletion with Fludarabine (30 mg/m<sup>2</sup>/day) x 4 days and Cyclophosphamide (500 mg/m<sup>2</sup>/day) x 2 days, patients underwent a single infusion of CARCIK-CD19 cells. The clinical trial follows a four-dose escalation scheme (1x10<sup>6</sup>, 3x10<sup>6</sup>, 7.5x10<sup>6</sup> and 15x10<sup>6</sup> transduced CAR+ T cells/kg) and was planned to include up to 18 patients treated in cohorts of three. The dose assignment for patients who sequentially entered the study was pre-specified according to the Bayesian Optimal Interval Design (BOIN) (62), a novel design with desirable statistical properties and performance superior to the traditional 3+3 design. The threshold for toxicity was set at 30% and decision rules for the conduction of the trial were guided by the observed rate of dose-limiting toxicity and are depicted in Supplementary Table 6. During the cell manufacturing period, bridging anti leukemic therapy from patient registration to the beginning of lymphodepletion, was allowed. Products were thawed at bedside in the pediatric setting and in the Cell Factory in the adult setting.

#### *Assessment of clinical response*

The primary endpoint of this study was to define the Maximum Tolerated Dose (MTD) and the safety assessment. Toxicity was graded using the NCI CTCAE (v4.03, Supplemental Table 7) (28, 63).

Key secondary endpoints included the assessment of complete hematologic response (CR), defined as < 5% abnormal blasts in BM, < 1% circulating blasts, restoration of normal hematopoiesis and no clinical evidence of extramedullary disease, as well as the measurement of CAR T cell persistence in PB and BM. CR with incomplete blood count recovery (CRi) is defined when all criteria for CR are met but not having adequate neutrophils ( $\leq 1.0 \times 10^9/L$ ) and platelets ( $\leq 100 \times 10^9/L$ ). Minimal

residual disease (MRD) was assessed by morphology and flow cytometry (limit of detection 1:10,000) and, in those patients with a known molecular marker, by QPCR.

#### *Detection of integrated copy number by quantitative PCR*

DNA was extracted from cultured T cells using QIAamp DNA mini kit (Qiagen, Hilden), according to manufacturer's instructions. Quantitative real-time PCR was performed on 100 ng of genomic DNA using TaqMan Gene Expression Master Mix (Applied Biosystem, Waltham, MA) and TaqMan Q-PCR (RT-PCR System QuantStudio 3, Applied Biosystems, CA), by comparison of hRNaseP Q-PCR results with VCN Q-PCR. This method has been developed from previous studies (24, 64, 65) and validated at Laboratorio Tettamanti according to international guidelines (LOQ, <50 copies/ $\mu$ g). The following primers and probes for the IR/DR sequences were used:

Tr-VCN-Fw CTCGTTTTTCAACTACTCCACAAATTTCT

Tr-VCN-Rv GTGTCATGCACAAAGTAGATGTCCTA

Tr-VCN-PR (FAM)-labeled MGB probe CTGACTTGCCAAAAC

#### *Pharmacokinetic analysis*

The maximum observed concentration (C<sub>max</sub>), the time to the maximum observed expansion (T<sub>max</sub>) and the area under the expansion time curve (AUC) at 28 days and at the last observation were calculated. AUCs were estimated through the trapezoidal rule.

#### *Assessment of CAR T cell persistence by flow cytometry*

PB and BM samples were obtained from patients either before CARCIK-CD19 infusion or at multiple time-points after infusion. Flow cytometry was performed to identify CD4<sup>+</sup> and CD8<sup>+</sup> CAR T cells as well as viable CD45<sup>+</sup>CD3<sup>+</sup>CAR<sup>+</sup> cells by incubation with CD19his (Thermo Fisher) and anti His

(Miltenyi Biotec, Bergisch Gladbach, North Rhine-Westphalia, Germany). Absolute CAR T cell counts were determined by correlation of the percentage of positive population to WBC. Details on the antibodies used for immunophenotyping are reported in Supplemental Table 8.

#### *Evaluation of serum cytokines*

Serum concentrations of GM-CSF, IFN- $\gamma$ , IL-10, IL-12P70, IL-13, IL-15, IL-17, IL-1RA, IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, TNF- $\alpha$ , TNF- $\beta$  were evaluated using MAGPIX<sup>®</sup> system (Millipore, Merck KGaA, Darmstadt, Germany), combined with MILLIPLEX<sup>®</sup> magnetic bead-based multi-analyte panels according to the manufacturer's protocol. The detection limits of the assay were between 0.7 to 8.3 pg/ml, depending on the cytokine.

#### *Integration Site retrieval protocol bioinformatics analysis*

Transposon IS were retrieved and sequenced as previously described in (66). Amplified PCR products, containing the vector/cell genome junctions (the integration sites, IS), were quantified by qPCR in order to compose equimolar sequencing libraries. Additional details regarding the IS retrieval protocol are provided in the Supplemental Methods section. Sequencing libraries of pooled PCR products were sequenced with the MiSeq Illumina platform. All sequence data obtained in the integration site analysis study are available at National Center for Biotechnology Information Sequence Read Archive (NCBI SRA) under public data accession number PRJNA643365. Of note, the in vivo samples harvested at the latest time points yield low amounts of PCR products and needed dedicated sequencing runs. Sequencing reads were processed by a dedicated bioinformatics pipeline (VISPA2) as previously describe (67). Briefly, paired sequence reads are filtered for quality standards, barcodes identified for sample de-multiplexing of the sequence reads, the cellular genomic sequence mapped on the reference Human genome (Human Genome\_GRCh37/hg19 Feb.

2019), and the nearest RefSeq gene assigned to each unambiguously mapped integration site. CIS analysis was performed using the Grubbs test for outliers, which allows to identify genes in which insertions are significantly enriched with respect the average gene integration frequency. For the quantification of the abundance of each clone we adopted an estimation method, SonicLength, based on the analysis of sheared DNA fragments containing the same IS (68). We used custom R scripts to combine data from different samples, filter dataset on the known IS, and produce graphical results.

### *Statistics*

Categorical data were summarized by counts and percentages, while continuous data were described with measures of location (i.e. arithmetic or geometric mean, median) and variability (i.e. range, standard deviation, coefficient of variation), as appropriate.

The remission rate estimates were reported along with 95% exact Clopper-Pearson Confidence Intervals (CI). Statistical analyses were performed with SAS 9.4 except those on GMP manufacture and CAR T persistence that were performed with GraphPad Prism 5.0. The duration of response was defined as the time from the achievement of the CR at 28 days to the time of progression. The duration of the follow-up was calculated from the time of the infusion.

### *Study approval*

The phase I/II study entitled “Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT (CARCIK)” was performed in accordance with European Medicines Agency (EMA), approved by Italian Regulatory Central Authorities and of the Local Ethical Committees and registered (EudraCT 2017-00900-38 and at ClinicalTrials.gov Identifier:

NCT03389035). Written consent was obtained from patients or their guardians in compliance with institutional guidelines and the Helsinki Declaration.

#### *Author contributions*

CFM and GG contributed equally to this work. CFM is the study scientific leader who developed the cellular product, collected and analyzed the data and wrote the paper. GG is the head of the GMP facility and of the cytometry facility, who led the production of the cellular product and the immune-monitoring post infusion and contributed in writing the manuscript. CFM, GG, FL, AdB, EB, GD, AR and AB conceptualized and designed the trial. AR and AB are the principal investigators of the study and revised the paper. AdB and FL are the co-investigators and revised the paper. GD are the clinical study manager. DB, GM, BC, CB, GMB, GF, SZ, ST, SC, VC, FB performed experiments. GC, EM, MI designed the experiments. GG, SN, AR provided medical care for the patients. SG and MGV designed the clinical trial and performed the statistical analyses.

#### *Acknowledgments*

This work was supported by: AIRC IG 2017: 20564; CRUK/AIRC/FC AECC 22791; Ricerca Finalizzata-Giovani Ricercatori GR-2016-02363491; AIRC Molecular Clinical Oncology 5 per mille 21147 and “CAR-T” project of the “Rete Oncologica”-Ministero Salute. The authors would like to thank Laurence J Cooper for providing the SB plasmids; Silvia Rigamonti, Alessio Stevano, and Marianna Ponzo for assistance in experiments; Riccardo and Donatella Ruschi and “Amici di Duccio” association, “Quelli che... con Luca” association, “Comitato Maria Letizia Verga”, Fondazione Benedetta è la vita ONLUS, and “Comitato Stefano Verri” for support; Markus G Manz, and Renier Myburgh for scientific discussion.



## References

1. Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. *Nat Med*. 2019;25(9):1341–1355.
2. Borowitz MJ et al. Prognostic significance of minimal residual disease in high risk B-ALL: A report from Children's Oncology Group study AALL0232. *Blood*. 2015;126(8):964–971.
3. Bassan R et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). *Blood*. 2009;113(18):4153–4162.
4. Gökbüget N et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. *Blood*. 2012;120(10):2032–2041.
5. Maude SL et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med*. 2018;378(5):439–448.
6. Gardner RA et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. *Blood*. 2017;129(25):3322–3331.
7. Turtle CJ et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. *J Clin Invest*. 2016;126(6):2123–2138.
8. Park JH et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. *N Engl J Med*. 2018;378(5):449–459.
9. Curran KJ et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. *Blood*. 2019;134(26):2361–2368.
10. Ghorashian S et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. *Nat Med*. 2019;25(9):1408–1414.
11. Frigault MJ, Maus M V. State of the art in CAR T cell therapy for CD19+ B cell malignancies. *J Clin Invest*. 2020;130(4):1586–1594.
12. Finney OC et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. *J Clin Invest*. 2019;129(5):2123–2132.
13. Fraietta JA et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nat Med*. 2018;24(5):563–571.
14. Ruella M et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. *Nat Med*. 2018;24(10):1499–1503.
15. Schmidt-Wolf IGH, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. *J Exp Med*. 1991;174(1):139–149.
16. Rambaldi A, Biagi E, Bonini C, Biondi A, Intronà M. Cell-based strategies to manage leukemia relapse: Efficacy and feasibility of immunotherapy approaches. *Leukemia*. 2015;29(1):1–10.
17. Intronà M et al. Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2017;23(12):2070–2078.
18. Merker M et al. Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions. *Biol Blood Marrow Transplant*. 2019;25(7):1281–1292.
19. Ivics Z, Izsvák Z, Minter A, Hackett PB. Identification of functional domains and evolution of Tc1-like transposable elements. *Proc Natl Acad Sci U S A*. 1996;93(10):5008–5013.
20. Ivics Z, Hackett PB, Plasterk RH, Izsvák Z. Molecular reconstruction of sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells. *Cell*. 1997;91(4):501–510.
21. Kebriaei P et al. Phase I trials using sleeping beauty to generate CD19-specific CAR T cells. *J Clin Invest*. 2016;126(9):3363–3376.


22. Magnani CF et al. Immunotherapy of acute leukemia by chimeric antigen receptormodified lymphocytes using an improved Sleeping Beauty transposon platform. *Oncotarget*. 2016;7(32):51581–51597.
23. Turazzi N et al. Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia. *Br J Haematol*. 2018;182(6):939–943.
24. Magnani CF et al. Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia. *Hum Gene Ther*. 2018;29(5):602–613.
25. Muffly L et al. Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation. *Blood Adv*. 2018;2(6):681–690.
26. Hackett PB, Largaespada DA, Cooper LJJ. A transposon and transposase system for human application. *Mol Ther*. 2010;18(4):674–683.
27. European Commission (b). EudraLex - Volume 4 - Good Manufacturing Practice (GMP) guidelines - European Commission. *Eur Comm Public Heal*. 2017;
28. Lee DW et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. 2014;124(2):188–195.
29. Nishimura R et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. *Blood*. 2008;112(6):2563–2574.
30. Firouzi S et al. Development and validation of a new high-throughput method to investigate the clonality of HTLV-1-infected cells based on provirus integration sites. *Genome Med*. 2014;6(6):46.
31. Levine BL, Miskin J, Wonnacott K, Keir C. Global Manufacturing of CAR T Cell Therapy. *Mol Ther - Methods Clin Dev*. 2017;4:92–101.
32. Schuster SJ et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med*. 2019;380(1):45–56.
33. Roddie C, O'Reilly M, Dias Alves Pinto J, Vispute K, Lowdell M. Manufacturing chimeric antigen receptor T cells: issues and challenges. *Cytotherapy*. 2019;21(3):327–340.
34. Kebriaei P, Izsák Z, Narayanavari SA, Singh H, Ivics Z. Gene Therapy with the Sleeping Beauty Transposon System. *Trends Genet*. 2017;33(11):852–870.
35. Mátés L et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. *Nat Genet*. 2009;41(6):753–761.
36. Clauss J et al. Efficient Non-Viral T-Cell Engineering by Sleeping Beauty Minicircles Diminishing DNA Toxicity and miRNAs Silencing the Endogenous T-Cell Receptors. *Hum Gene Ther*. 2018;29(5):569–584.
37. Querques I et al. A highly soluble Sleeping Beauty transposase improves control of gene insertion. *Nat Biotechnol*. 2019;37(12):1502–1512.
38. Introna M et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study. *Haematologica*. 2007;92(7):952–959.
39. Introna M et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: An innovative proposal for the treatment of leukemia relapse after cord blood transplantation. *Bone Marrow Transplant*. 2006;38(9):621–627.
40. Provati E et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. *Nat Med*. 2012;18(5):807–815.
41. Qasim W et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. *Sci Transl Med*. 2017;9(374). doi:10.1126/scitranslmed.aaj2013
42. Stadtmauer EA et al. CRISPR-engineered T cells in patients with refractory cancer. *Science*. 2020;367(6481). doi:10.1126/science.aba7365
43. Bailey SR, Maus MV. Gene editing for immune cell therapies. *Nat Biotechnol*. 2019;37(12):1425–

1434.


44. Liu E et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. *N Engl J Med*. 2020;382(6):545–553.
45. Liu E et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. *Leukemia*. 2018;32(2):520–531.
46. Maluski M et al. Chimeric antigen receptor-induced BCL11B suppression propagates NK-like cell development. *J Clin Invest*. 2019;129(12):5108–5122.
47. Brandjes BD, Davila ML. Adding chimeric antigen receptor-induced killer cells to the medical oncology shelf. *J Clin Invest*. 2019;129(12):5077–5078.
48. Mueller KT et al. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. *Clin Cancer Res*. 2018;24(24):6175–6184.
49. Maude SL et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med*. 2014;371(16):1507–1517.
50. Pulè MA et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. *Mol Ther*. 2005;12(5):933–941.
51. Guedan S et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. *JCI insight*. 2018;3(1). doi:10.1172/jci.insight.96976
52. Zhao Z et al. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. *Cancer Cell*. 2015;28(4):415–428.
53. Teachey DT et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. *Cancer Discov*. 2016;6(6):664–679.
54. de Jong J et al. Chromatin landscapes of retroviral and transposon integration profiles. *PLoS Genet*. 2014;10(4):e1004250.
55. Cesana D et al. HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells. *Nat Commun*. 2017;8(1):498.
56. Shah NN et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. *Blood Adv*. 2019;3(15):2317–2322.
57. Fraietta JA et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. *Nature*. 2018;558(7709):307–312.
58. Nobles CL et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. *J Clin Invest*. 2020;130(2):673–685.
59. Spyridonidis A et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. *Leukemia*. 2012;26(6):1211–1217.
60. Challita PM et al. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. *J Virol*. 1995;69(2):748–755.
61. Geurts AM et al. Gene transfer into genomes of human cells by the Sleeping Beauty transposon system. *Mol Ther*. 2003;8(1):108–117.
62. Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian optimal interval design: A simple and well-performing design for phase I oncology trials. *Clin Cancer Res*. 2016;22(17):4291–4301.
63. Lee DW et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow Transplant*. 2019;25(4):625–638.
64. Kolacsek O et al. Excision efficiency is not strongly coupled to transgenic rate: Cell type-dependent transposition efficiency of sleeping beauty and piggy bac DNA transposons. *Hum Gene Ther Methods*. 2014;25(4):241–252.
65. van der Velden VHJ et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements:

- Guidelines for interpretation of real-time quantitative PCR data. *Leukemia*. 2007;21(4):604–611.
66. Markt S et al. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent  $\alpha$ -thalassemia. *Nat Med*. 2019;25(2):234–241.
67. Spinozzi G et al. VISPA2: a scalable pipeline for high-throughput identification and annotation of vector integration sites. *BMC Bioinformatics*. 2017;18(1):520.
68. Berry CC et al. Estimating abundances of retroviral insertion sites from DNA fragment length data. *Bioinformatics*. 2012;28(6):755–762.


Figures and figure legends



**Figure 1. Cell expansion and composition of manufactured medicinal products.** (A) Expansion kinetics of 19 different batches are represented as total number of nucleated cells (TNC) overtime. Each line represents a single batch. (B) Viability of TNC overtime (n=19). The arrow indicates the time point when the electroporation was performed. (C) Flow cytometric immunophenotyping by dual density plots in one representative batch (n=9). CD3+ cells were selected by CD3/SSC gating (left), then CD3+/CAR+ cells were gated and then CD4/CD8, CD45RO/CD62L and CD3/CD56 expression were measured. (D) Expression of CD3+, CAR+, CD56+, CD4+, CD8+ cells as percentage of TNCs. Each symbol represents a single batch. (E) Expression of CD56+, CD4+ and CD8+ cells as percentage of CD3+/CAR+ T cells. Each symbol represents a single batch. (F) Expression of Naive, Central Memory (CM), Effector Memory (EM) and Terminal Effector (EMRA) cells as percentage of CD3+/CAR+ T cells. Mean are shown as horizontal line.




**Figure 2. Study Flow.** Study participants flow chart from the time of screening to treatment.




**Figure 3. Post-infusion expansion and persistence of CAR T cells in PB according to dose level.**

Transgene copy number per  $\mu\text{g}$  in blood (A), percentage of CAR+ T cells within the total CD3+ T cells in blood (B), absolute counts of CAR+CD3+ cells in blood (C) measured at different intervals of time after CARCIK-CD19 infusion in patients treated at different dose levels. Each symbol and colour codify an individual patient sample ( $n=13$ ). Measures under the limit of quantification (LOQ,  $<50$  copies/ $\mu\text{g}$ ) were inserted in the graphs with a fixed reference value. (D) Flow cytometric dual density plots showing leukemic blast clearance assessed as minimal residual disease (MRD) detection and CAR T cell engraftment in BM (upper panels) and PB (bottom panels) at different time points in patient 13. MRD, minimal residual disease; BM, bone marrow; PB, peripheral blood; WBC, white blood cells. Numbers within the diagrams represent the percentages of cells. (E) AUC-28d according to dose level. (F) Tmax-28d according to dose level. (G) Tmax-28d according to dose level. Each symbol represents a single patient ( $n=13$ ). AUC, area under the curve (transgene copies/ $\mu\text{g}$  DNA); 28d, measurement from time 0 to 28; Tmax, time to reach peak expansion; Cmax, maximum concentration.




**Figure 4. Post-infusion immunophenotype and kinetic of CAR T cells.** (A) Percentage of CD3+CD8+, CD3+CD4+ and CD3+CD56+ cell subsets within the CAR+CD3+ T cells in PB at different intervals of time after CARCIK-CD19 infusion (n=11). (B) Expression of Naive, Central Memory (CM), Effector Memory (EM) and Terminal Effector (EMRA) cells as percentage of CAR+CD3+ T cells in PB at different intervals of time after CARCIK-CD19 infusion (n=11). (C) Flow cytometric dot plots showing the phenotype of circulating CAR T cells in a representative B-ALL patient at 21 days after CARCIK-CD19 infusion (n=13).





**Figure 5. Clinical outcome and anti-leukemic response duration.** (A) Waterfall plot of individual patient BCA duration. (B) Waterfall plot of individual patient remission duration (n=13), remission duration in presence of transgene copy number and timing of relapse, allogeneic (allo-) HSCT and eventually death. (C) CT-scan at baseline and 44 days post CARCIK-CD19 infusion in patient 12 with a diffuse B-ALL presenting with liver massive infiltration. CR, complete remission; VCN, vector copy number; PD, progressive disease; BCA, B cell aplasia.



**Figure 6. Transposon integration site analyses in patient peripheral blood and cellular products.** (A) Experimental and analytical workflow adopted for the integration site retrieval and analysis in vitro and in vivo samples. (B) Frequency distribution of SB IS around genes' TSS (interval  $\pm 10$  Kb divided in 500 bp bins) in vitro (black bars) and in vivo (gray bars), expressed as percent relative to the total IS for each dataset ( $n=40$  samples). (C) CIS analysis was performed on the IS identified for each patient using the Grubbs test for outliers and volcano plot representation. All genes targeted by IS are tested and plotted with dots of size proportional to the gene length; gene integration frequency normalized by gene length is placed on the x-axis, while the y-axis shows the P-value of CIS Grubbs test for outliers ( $-\log$  base 10 of P-value). Tumor suppressor genes are annotated in blue, proto-oncogene in red, and a generic "other" in green for the remaining genes. Dots with significant P-values (alpha threshold of 0.05) are above the dashed horizontal line and labelled with the closest gene name (RefSeq). Gene ID labels of genes involved in clonal expansion of genetically modified cells were annotated using red labels, tumor suppressor genes using orange labels or genes with other functions in blue. (D) For each patient, the clonal abundance of IS represented by at least two sequencing reads are represented with a stacked bar plot in which each clone is represented by a different color and the height is proportional to the relative percentage of genomes of the specific integration site over the total genomes; each bar represents a specific time point after infusion; ribbons connect tracked clones between two consecutive time points. Four out of 11 patients are represented. (E) Shannon Diversity (H) index was calculated for the IS datasets obtained from each patient over time ( $n=13$ ).

**Table 1. Patient characteristics**

#	Patient ID	Age <sup>A</sup>	Sex	Cytogenetics	Prior Lines of Therapy	Type of Transplant Donor	N of previous HSCT	Disease status at HSCT <sup>H</sup>	Months from Allo-HSCT to Relapse	aGVHD post last HSCT	cGVHD post last HSCT	BM Blasts at enrollment	Extramedullary disease	Bridge Chemotherapy	BM Blasts post lymphodepletion (% , PCR)
1	11010001	5	F <sup>B</sup>	t(9;18) PAX5/ZNF521	5	Haplo <sup>E</sup>	1	HCR, PCR+	3	None	None	98%	Adenoids	VCR <sup>I</sup> +DEXA <sup>J</sup>	96% PCR+
2	21020001	27	M <sup>C</sup>	Hyperdiploid	3	MUD <sup>F</sup>	1	HCR, PCR-	18	G-I (skin)	G-II (skin)	90%	None	CY <sup>K</sup> , VCR, ARA-C <sup>L</sup> , VP-16 <sup>M</sup>	13% PCR+
3	21020002	56	M	n.a. <sup>D</sup>	1	Haplo	1	Hemato PR	4	G-II (skin, gut)	None	40%	None	6-MP <sup>N</sup>	70% PCR+
4	21020004	62	F	t(9;22) Bcr/Abl1	2	Haplo	1	HCR, PCR+	8	None	None	60%	None	Inotuzumab	0% PCR+
5	21020007	45	F	t(9;22) Bcr/Abl1	2	ISD <sup>G</sup>	2	HCR, PCR+	10	G-I (skin)	G-I (skin, liver)	90%	None	Inotuzumab	0% PCR-
6	11010004	10	M	t(4;11) MLL- AF4	1	MUD	1	HCR, PCR+	9	G-III (skin, gut, liver)	None	5%	Spinal Cord	Blinatumomab	0% n.a.
7	11010003	2	F	t(4;11) MLL- AF4	1	MUD	1	HCR, PCR+	4	G-I (skin)	None	34%	None	L-asp <sup>O</sup> , VCR, doxo <sup>P</sup> , PRD <sup>Q</sup>	0% PCR+
8	11010005	7	M	Complex karyotype	2	Haplo	1	HCR, PCR-	11	G-I (skin)	None	8%	None	CY, VCR, VP16, ARA-C, 6-MP	0% PCR-
9	21020010	32	F	normal karyotype	3	ISD	2	HCR, PCR+	30	None	None	50%	Small pectoral muscle	CY, E <sup>R</sup> , VCR	48% PCR+
10	21020011	39	F	Complex karyotype	6	Haplo	2	HCR, PCR+	3	None	G-I (liver)	8%	None	6-MP	0.14% PCR+
11	21020013	63	M	t(9;22) Bcr/Abl1	2	MUD	1	HCR, PCR-	24	None	None	30%	None	VCR, DEXA	0.17% PCR+
12	21020014	52	F	Hyperdiploid	2	ISD	1	HCR, PCR+	2	G-I (skin)	G-I (skin)	95%	Liver; Pancreas	<sup>S</sup> EDX, VCR; DEX, VP-16, ARA-C	62% PCR+
13	21020015	30	M	Complex karyotype	7	Haplo	2	HCR, PCR+	15	None	None	60%	None	VCR, Purinethol	53% PCR+

<sup>A</sup>Age= Years; <sup>B</sup>F= female; <sup>C</sup>M= male; <sup>D</sup>n.a.= not available; <sup>E</sup>Haplo= haploidentical donor; <sup>F</sup>MUD= matched unrelated donor; <sup>G</sup>ISD= HLA identical sibling; <sup>H</sup>allo-HSCT= allogeneic hematopoietic stem cell transplantation; <sup>I</sup>VCR= vincristine; <sup>J</sup>DEXA= dexamethasone; <sup>K</sup>CY= Cyclophosphamide; <sup>L</sup>ARA-C= Cytarabin; <sup>M</sup>VP16= Etoposid; <sup>N</sup>6-MP= 6-Mercaptopurin; <sup>O</sup>L-asp= L-asparaginase; <sup>P</sup>doxo= doxorubicin; <sup>Q</sup>PRD= prednisone; <sup>R</sup>E= Epirubicine; <sup>S</sup>EDX= Endoxan; aGVHD= acute GVHD; cGVHD= chronic GVHD

**Table 2. Toxicity and response to therapy**

Patient ID	Dose (10 <sup>6</sup> /Kg)	GVHD	CRS <sup>A</sup>	Neurotoxicity	Disease response (Day 28)	MRD qPCR BM (Day 28)	Duration of response (months from CR)	Overall survival from infusion (months)	Current status
1 11010001	1	None	None	None	NR <sup>B</sup>	POS	-	1.0	Dead
2 21020001	1	None	None	None	NR	POS	-	20.0 <sup>G</sup>	Alive
3 21020002	1	None	None	None	NR	POS	-	1.6	Dead
4 21020004	3	None	None	None	CR <sup>C</sup>	POS	1.4	4.0	Dead
5 21020007	3	None	None	None	CR	NEG	3.9	9.8	Dead
6 11010004	3	None	None	None	NR* <sup>D</sup>	POS	-	6.1	Dead
7 11010003	7.5	None	None	None	CR	NEG	8.7 <sup>F</sup>	9.6 <sup>H</sup>	Alive
8 11010005	7.5	None	None	None	CR	NEG	7.8 <sup>F</sup>	8.7 <sup>H</sup>	Alive
9 21020010	7.5	None	None	None	NR	POS	-	7.8 <sup>I</sup>	Alive
10 21020011	15	None	Grade 1	None	CR	POS	1.0	6.1	Alive
11 21020013	15	None	None	None	CR	NEG	4.6 <sup>F</sup>	5.4	Alive
12 21020014	15	None	Grade 2	None	CRi <sup>E</sup>	NEG	1.1	2.2	Dead
13 21020015	15	None	Grade 1	None	CR	NEG	2.2 <sup>F</sup>	3.1	Alive

<sup>A</sup>CRS= cytokine release syndrome; <sup>B</sup>NR= no response; <sup>C</sup>CR= complete response; <sup>D</sup>NR\*= CR in BM with Extramedullary Disease; <sup>E</sup>CRi= CR with incomplete recovery; <sup>F</sup>§= ongoing response; <sup>G</sup>patient 2 received Inotuzumab (0.83 mos from infusion) and, subsequently, HSCT; <sup>H</sup>patient 7 and 8 underwent HSCT (2.08 e 5.32 mos from infusion, respectively); <sup>I</sup>patient 9 received Inotuzumab (3.74 mos from infusion)